A dual-targeting anticancer approach: Soil and seed principle

Radiology

Volumn 260, Issue 3, 2011, Pages 799-807

  Li, Junjie ^a   Sun, Ziping ^b   Zhang, Jian ^c   Shao, Haibo ^d   Cona, Marlein Miranda ^a   Wang, Huaijun ^a   Marysael, Thierry ^a   Chen, Feng ^a,e   Prinsen, Kristof ^a   Zhou, Lin ^a   Huang, Dejian ^c   Nuyts, Johan ^a   Yu, Jie ^a   Meng, Bin ^b   Bormans, Guy ^a   Fang, Zhijun ^c   De Witte, Peter ^a   Li, Yaming ^d   Verbruggen, Alfons ^a   Wang, Xiaoning ^c   Mortelmans, Luc ^a   Xu, Ke ^d   Marchal, Guy ^a   Ni, Yicheng ^a,b,c,d,e   more..

^a UNIVERSITY OF LEUVEN   (Belgium)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c Jiangsu Academy of Traditional Chinese Medicine   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; GADOTERATE MEGLUMINE; HYPERICIN I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; EX VIVO STUDY; HUMAN; IN VIVO STUDY; IONIZING RADIATION; LIVER RHABDOMYOSARCOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RAT; RHABDOMYOSARCOMA; SCINTIGRAPHY; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; IODINE RADIOISOTOPES; PERYLENE; RADIOPHARMACEUTICALS; RATS; RHABDOMYOSARCOMA; TREATMENT OUTCOME;

EID: 84860390456     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11102120     Document Type: Article

References (29)

1. Aggarwal B.B., Danda D., Gupta S., Gehlot P. Models for prevention and treatment of cancer: Problems vs promises. Biochem Pharmacol 2009;78(9):1083-1094.
2. Ni Y., Mulier S., Miao Y., Michel L., Marchal G. A review of the general aspects of radiofrequency ablation. Abdom Imaging 2005;30(4):381-400. (Pubitemid 41176116)
3. Ni Y., Van de Putte M., De Witte P., Verbruggen A., Marchal G., Sun Z Targeted radiotherapy WO 2009/067767 International patent application PCT-2008-000099 Priority date: November 27, 2007.
4. Wang H., Sun X., Chen F., et al. Treatment of rodent liver tumor with combretastatin a4 phosphate: Noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 2009;44(1):44-53.
5. Delmonte A., Sessa C. AVE8062: A new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009;18(10):1541-1548.
6. Ni Y., Huyghe D., Verbeke K., et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 2006;33(5):595-601.
7. Fonge H., Vunckx K., Wang H., et al. Noninvasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur Heart J 2008;29(2):260-269. (Pubitemid 351164878)
8. Ni Y., Bormans G., Marchal G., Verbruggen A Necrosis avid tracer agent European patent EP1651201B1 January 2, 2008. Priority date: July 25, 2003.
9. Van de Putte M., Wang H., Chen F., De Witte P.A., Ni Y. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep 2008;19(4):927-932. (Pubitemid 351802661)
10. Ni Y., Bormans G., Chen F., Verbruggen A., Marchal G. Necrosis avid contrast agents: Functional similarity versus structural diversity. Invest Radiol 2005;40(8):526-535. (Pubitemid 41040690)
11. Ni Y. Metalloporphyrins and functional analogues as MRI contrast agents. Curr Med Imaging Rev 2008;4(2):96-112. (Pubitemid 351890566)
12. Dorn R., Kopp J., Vogt H., Heidenreich P., Carroll R.G., Gulec S.A. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med 2003;44(3):451-456. (Pubitemid 39586024)
13. Chen F., Sun X., De Keyzer F., et al. Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology 2006;239(2):554-562.
14. Wu X., Wang H., Chen F., et al. Rat model of reperfused partial liver infarction: Characterization with multiparametric magnetic resonance imaging, microangiography, and histomorphology. Acta Radiol 2009;50(3):276-287.
15. Ni Y., Wang H., Chen F., et al. Tumor models and specific contrast agents for small animal imaging in oncology. Methods 2009;48(2):125-138.
16. Ni Y., Marchal G., Yu J., et al. Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: Comparison of magnetic resonance imaging, microangiographic, and histologic findings. Acad Radiol 1995;2(8):687-699.
17. Ni Y., Petré C., Miao Y., et al. Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol 1997;32(12):770-779. (Pubitemid 28053509)
18. Ni Y., Marchal G., Herijgers P., et al. Paramagnetic metalloporphyrins: From enhancers of malignant tumors to markers of myocardial infarcts. Acad Radiol 1996;3(Suppl 2):S395-S397.
19. Pislaru S.V., Ni Y., Pislaru C., et al. Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation 1999;99(5):690-696. (Pubitemid 29077369)
20. Ni Y., Pislaru C., Bosmans H., et al. Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol 2001;11(5):876-883. (Pubitemid 32755542)
21. Ni Y., Chen F., Mulier S., et al. Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: Tis sue characterization using a novel necrosis-avid contrast agent. Eur Radiol 2006;16(5):1031-1040.
22. Ni Y., Cresens E., Adriaens P., et al. Necrosis-avid contrast agents: Introducing nonporphyrin species. Acad Radiol 2002;9(Suppl 1):S98-S101. (Pubitemid 34441454)
23. Jin J.Y., Teng G.J., Feng Y., et al. Magnetic resonance imaging of acute reperfused myocardial infarction: Intraindividual comparison of ECIII-60 and Gd-DTPA in a swine model. Cardiovasc Intervent Radiol 2007;30(2):248-256. (Pubitemid 46147116)
24. Chen F.M., Taylor C.R., Epstein A.L. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49(16):4578-4585. (Pubitemid 19208364)
25. Chen Y.C., Chen S.L., Ju D.W., Shi H.C., Xu K.P., Xu C.D. Pharmacokinetics of iodine-131-labeled chimeric monoclonal antibody in lung cancer patients. J China Pharm Univ 2004;35:164-167.
26. Loh K.C., Fitzgerald P.A., Matthay K.K., Yeo P.P., Price D.C. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20(11):648-658. (Pubitemid 28056835)
27. Chang C.H., Sharkey R.M., Rossi E.A., et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1(7):553-563.
28. Ginj M., Chen J., Walter M.A., Eltschinger V., Reubi J.C., Maecke H.R. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11(3):1136-1145. (Pubitemid 40175763)
29. Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: What have we learned after 50 years? J Nucl Med 1993;34(10):1638-1641. (Pubitemid 23295370)